Treats Parkinson’s disease, post-encephalitic parkinsonism, and symptomatic parkinsonism. ANDA 75091, held by Mylan. Carbidopa; Levodopa.
As of Nov 16, 2026, ANDA 75091 (Carbidopa And Levodopa), held by Mylan, was first approved by FDA on Sep 30, 1999, with 11 approved supplements and 0 published complete response letters.
INDICATIONS AND USAGE Carbidopa and levodopa extended-release tablets are indicated in the treatment of Parkinson’s disease, post-encephalitic parkinsonism, and symptomatic parkinsonism that may follow carbon monoxide intoxication or manganese intoxication.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Sep 30, 1999 | Original application | Approved |
| Carbidopa And Levodopa50MG;200MG · tablet, extended release;oral | Carbidopa; Levodopa | Rx |
| Carbidopa And Levodopa25MG;100MG · tablet, extended release;oral | Carbidopa; Levodopa | Rx |
| Oct 8, 2026 | Supplement 36Labeling · Standard review | Approved | None posted |
| May 27, 2015 | Supplement 26Labeling · Standard review | Approved | None posted |
| May 14, 2012 | Supplement 24Labeling | Approved | None posted |
| Oct 1, 2002 | Supplement 8Manufacturing | Approved | None posted |
| Jun 12, 2002 | Supplement 7Manufacturing | Approved | None posted |
| Nov 7, 2001 | Supplement 6Labeling | Approved | None posted |
| Aug 11, 2000 | Supplement 5Manufacturing | Approved | None posted |
| Aug 11, 2000 | Supplement 4Manufacturing | Approved | None posted |
| Apr 21, 2000 | Supplement 2Labeling | Approved | None posted |
| Apr 21, 2000 | Supplement 1Manufacturing | Approved | None posted |
| Feb 4, 2000 | Supplement 3Labeling | Approved | None posted |
| Sep 30, 1999 | Original application | Approved |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters